N. Bhagwat

发表

Combining Machine Learning and Nanofluidic Technology To Diagnose Pancreatic Cancer Using Exosomes.

D. Issadore, J. Ko, N. Bhagwat, 2017, ACS nano.

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

J. Licht, O. Abdel-Wahab, A. Melnick, 2010, Cancer cell.

Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.

S. Armstrong, A. Ferrando, J. Teruya-Feldstein, 2015, Blood.

Flow Cytometric Methods for Circulating Tumor Cell Isolation and Molecular Analysis.

N. Bhagwat, E. Carpenter, 2017, Advances in experimental medicine and biology.

PRMT5 inhibition modulates E2F1 methylation and gene regulatory networks leading to therapeutic efficacy in JAK2V617F mutant MPN.

K. Helin, R. Koche, R. Levine, 2020, Cancer discovery.

Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis.

R. Levine, N. Bhagwat, M. Kleppe, 2014, Blood.

Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms

R. Levine, N. Bhagwat, P. Koppikar, 2013, International Journal of Hematology.

A magnetic micropore chip for rapid (<1 hour) unbiased circulating tumor cell isolation and in situ RNA analysis.

A. Raj, D. Issadore, J. Ko, 2017, Lab on a chip.

An integrated enrichment system to facilitate isolation and molecular characterization of single cancer cells from whole blood

Liping Yu, Keely A. Dulmage, E. Dixon, 2018, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

A multi-analyte panel consisting of extracellular vesicle miRNAs and mRNAs, cfDNA, and CA19-9 shows utility for diagnosis and staging of pancreatic adenocarcinoma

D. Issadore, J. Ko, N. Bhagwat, 2020 .

PRMT5 inhibition modulates E2F1 methylation and gene regulatory networks leading to therapeutic efficacy in JAK2V617F mutant MPN.

K. Helin, R. Koche, R. Levine, 2019, Cancer discovery.

Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms

J. Teruya-Feldstein, O. Kilpivaara, R. Levine, 2019, Haematologica.

Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2

R. Levine, V. Sexl, B. Kovacic, 2014, Leukemia.

Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis

A. Tall, R. Levine, A. Murphy, 2013, Nature Medicine.

Heterodimeric JAK-STAT Activation as a Mechanism of Persistence to JAK2 Inhibitor Therapy

B. Bernstein, B. Ebert, Mazhar Adli, 2011, Nature.

Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms.

J. Qi, J. Bradner, R. Levine, 2014, Blood.

A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma

D. Issadore, J. Ko, N. Bhagwat, 2020, Clinical Cancer Research.

Predicting Targets for Genome Editing with Long Short Term Memory Networks

Natalia Khuri, Neha Bhagwat, N. Bhagwat, 2021, Advances in Computer Vision and Computational Biology.

Highly specific enrichment of rare nucleic acid fractions using Thermus thermophilus argonaute with applications in cancer diagnostics

H. Bau, M. Mauk, N. Bhagwat, 2019, Nucleic acids research.

Metastatic progression is associated with dynamic changes in the local microenvironment

Toby C. Cornish, C. Iacobuzio-Donahue, N. Bhagwat, 2016, Nature Communications.

Improved targeting of JAK 2 leads to increased therapeutic ef fi cacy in myeloproliferative neoplasms

J. Qi, J. Bradner, R. Levine, 2014 .

Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.

W. Sellers, R. Levine, F. Hofmann, 2012, Cancer discovery.

HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans.

K. Ross, M. Gönen, J. Bradner, 2010, The Journal of clinical investigation.

An integrated flow cytometry-based platform for isolation and molecular characterization of circulating tumor single cells and clusters

F. Tong, Liping Yu, Keely A. Dulmage, 2018, Scientific Reports.

JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.

Jonathan J. Chen, Franziska Michor, Omar Abdel-Wahab, 2015, Cancer discovery.

Highly Specific Enrichment of Rare Nucleic Acids using Thermus Thermophilus Argonaute

H. Bau, M. Mauk, N. Bhagwat, 2018, bioRxiv.

miRNA Profiling of Magnetic Nanopore-Isolated Extracellular Vesicles for the Diagnosis of Pancreatic Cancer.

Jina Ko, David Issadore, Neha Bhagwat, 2018, Cancer research.

Identification of a Novel Lysophospholipid Acyltransferase in Saccharomyces cerevisiae*

Charles Boone, M. Costanzo, Shilpa Jain, 2007, Journal of Biological Chemistry.

HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders

S. Cremers, O. Abdel-Wahab, A. Tall, 2013, The Journal of experimental medicine.

An integrated flow cytometry-based platform for isolation and molecular characterization of circulating tumor single cells and clusters

Ling Wang, Charles H Pletcher, Liping Yu, 2018, Scientific Reports.

Abstract 983: Preclinical characterization of PRT1419, a potent, selective and orally available inhibitor of MCL1

N. Bhagwat, P. Scherle, K. Vaddi, 2021, Experimental and Molecular Therapeutics.

HSP 90 is a therapeutic target in JAK 2-dependent myeloproliferative neoplasms in mice and humans

K. Ross, M. Gönen, J. Bradner, 2018 .

Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms.

J. Qi, J. Bradner, R. Levine, 2014, Blood.

Abstract 3263: Preclinical characterization of PRT3789, a potent and selective SMARCA2 targeted degrader

N. Bhagwat, P. Scherle, P. Pitis, 2022, Cancer Research.

PRT2527, a Novel Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, Has Potent Anti-Leukemic Activity in Preclinical Primary Models of Human B-ALL, T-ALL, and CLL

N. Bhagwat, P. Scherle, Yaron Mosesson, 2022, Blood.

JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.

Jonathan J. Chen, J. Teruya-Feldstein, O. Abdel-Wahab, 2015, Cancer discovery.

miRNA Profiling of Magnetic Nanopore-Isolated Extracellular Vesicles for the Diagnosis of Pancreatic Cancer.

Junhyong Kim, D. Issadore, J. Ko, 2018, Cancer research.

Non-canonical Hedgehog signaling mediates profibrotic hematopoiesis-stroma crosstalk in myeloproliferative neoplasms

O. Naveiras, R. Kramann, N. Bhagwat, 2023, Cell reports.